- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI restructures to focus on US contrast
Ultrasound contrast developer Molecular Biosystems has let go 25% of its staff and eliminatednon-ultrasound R&D programs in an effort to cut expenses.The San Diego firm, which developed the echocardiography agentAlbunex, said the move should save $6
Ultrasound contrast developer Molecular Biosystems has let go 25% of its staff and eliminatednon-ultrasound R&D programs in an effort to cut expenses.The San Diego firm, which developed the echocardiography agentAlbunex, said the move should save $6 million annually. MBI'sstock fell 23% to $7 a share on the news.
MBI last week said it terminated 48 employees from its 197-personwork force and discontinued R&D for MRI and CT agents. MBIwill continue developing Oralex, a gastrointestinal oral ultrasoundagent in phase-one trials, and FS069, a second-generation myocardialperfusion agent awaiting Food and Drug Administration approvalto begin phase-one studies (SCAN 7/27/94).
Earlier last month, MBI posted results for its third quarterof 1995 (end-December). The company recorded a net loss for thequarter of $2.2 million, compared to a net loss of $1.1 millionin the same period a year ago. MBI's revenues were $6.9 million,compared to $5.5 million in the third quarter of 1993. MBI's marketingpartner Mallinckrodt Medical began selling Albunex in the U.S.in October (SCAN 8/31/94).
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
